Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QDPR | P09417 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | THPO | P40225 | 1/20 | 0.46 |
| ▸ | HTR6 | P50406 | 2/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.43 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.43 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12393854 | 0.93 | QDPR (0.47) | QDPRCYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL24519848 | 0.89 | KDM4E (0.54) | QDPRSIGMAR1 | |
| SCHEMBL29566591 | 0.85 | QDPR (0.47) | QDPRCYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL24310108 | 0.84 | QDPR (0.46) | QDPRCYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL3992205 | 0.83 | MEN1 (0.50) | CYP1A2CYP3A4CYP2D6CYP2C9THPO | |
| SCHEMBL929830 | 0.83 | MEN1 (0.50) | CYP1A2CYP3A4CYP2D6CYP2C9THPO | |
| SCHEMBL5727474 | 0.82 | DRD2 (0.48) | HTR6 | |
| SCHEMBL23921755 | 0.82 | KCNH2 (0.47) | CYP2D6CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL17368685 | 0.81 | CYP1A2 (0.59) | QDPRCYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL13085385 | 0.80 | HTR2C (0.58) | HTR6SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210317134-A1 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF | RAPT THERAPEUTICS INC (US) | 2021-10-14 | — | — | US | disclosed |
| WO-2021070090-A1 | 2-AZASPIRO[3.4]OCTANE DERIVATIVES AS M4 AGONISTS | NOVARTIS AG (CH) | 2021-04-15 | — | — | WO | disclosed |
| WO-2020021021-A1 | ORTHO SUBSTITUTED PHENOXYPROPYLAMINO AND BENZYLOXYPROPYLAMINO DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2020-01-30 | — | — | WO | disclosed |
| US-8143287-B2 | Thrombopoietin mimetics | STATEGICS, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-8143287-B2 | Thrombopoietin mimetics | STATEGICS, INC. (US) | 2012-03-27 | — | — | US | disclosed |
| US-20100323965-A1 | Thrombopoietin Mimetics | STATEGICS, INC. (US) | 2010-12-23 | — | — | US | disclosed |
| US-20100323965-A1 | Thrombopoietin Mimetics | STATEGICS, INC. (US) | 2010-12-23 | — | — | US | disclosed |
| US-7786159-B2 | Thrombopoietin mimetics | STATEGICS, INC. (US) | 2010-08-31 | — | — | US | disclosed |
| US-7786159-B2 | Thrombopoietin mimetics | STATEGICS, INC. (US) | 2010-08-31 | — | — | US | disclosed |
| US-20080139621-A1 | Thrombopoietin Mimetics | STATEGICS, INC. (US) | 2008-06-12 | — | — | US | disclosed |
| US-20080139621-A1 | Thrombopoietin Mimetics | STATEGICS, INC. (US) | 2008-06-12 | — | — | US | disclosed |
| WO-2008070583-A2 | THROMBOPOIETIN MIMETICS | STATEGICS, INC. (US) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139621-A1 | Thrombopoietin Mimetics | MPL, THPO, TEK | QDPR 3134/4885CYP1A2 4132/4885CYP3A4 4742/4885 |
| US-20210317134-A1 | UBIQUITIN-SPECIFIC-PROCESSING PROTEASE 7 (USP7) MODULATORS AND USES THEREOF | USP7, SENP7, USP8 | QDPR 3769/4885CYP1A2 3993/4885CYP3A4 3186/4885 |
| US-20100323965-A1 | Thrombopoietin Mimetics | MPL, THPO, TEK | QDPR 3134/4885CYP1A2 4132/4885CYP3A4 4742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.